Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

GLP-1 weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

In this cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with reduced risk of developing ...

Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study ...

Patients with various combinations of CKM comorbidities who receive GLP-1RAs have decreased risk for HF hospitalization and CV death.

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial ...

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three ...

Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health risks in people with type 2 diabetes than other types of glucose-lowering ...

Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. The biopharmaceutical company said Tuesday it will not ...